Sign In
Buy FATE
$2.22
-0.350 (-13.62%)
At Close: Jun 03, 2026
Fate Therapeutics Q1 EPS $(0.440) Misses $(0.390) Estimate, Sales $2.515M Beat $1.800M Estimate
08:17pm, Monday, 11'th May 2020Fate Therapeutics Reports First Quarter 2020 Financial Results and Highlights Operational Progress
08:01pm, Monday, 11'th May 2020
Fate Therapeutics, Inc. (FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today reported business
The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight
12:00am, Sunday, 10'th May 2020
The smid-cap biotech earnings deluge hit Wall Street in the week ended May 9, positively impacting the stocks in the sector. The iShares NASDAQ Biotechnology Index (NASDAQ: IBB)...
Should You Buy Fate Therapeutics (FATE) Ahead of Earnings?
12:46pm, Friday, 08'th May 2020
Fate Therapeutics (FATE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Mantle Cell Lymphoma Treatment Market - Global Industry to Discern Magnified Growth During 2020-2027
02:40am, Friday, 08'th May 2020
May 07, 2020 (Global QYResearch via COMTEX) --
This report studies the global Mantle Cell Lymphoma Treatment market status and forecast, categorizes the...
Should You Buy Fate Therapeutics (FATE) Ahead of Earnings?
12:00am, Friday, 08'th May 2020Were Hedge Funds Right About Fate Therapeutics Inc (FATE)?
01:18am, Wednesday, 06'th May 2020
Coronavirus is probably the 1 concern in investors' minds right now. It should be. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW. We predicted
Fate Therapeutics Announces Changes to its Board of Directors
08:01pm, Tuesday, 05'th May 2020
Fate Therapeutics, Inc. (FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced the reti
Fate Therapeutics Announces Changes to its Board of Directors
12:00am, Tuesday, 05'th May 2020Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2020 Financial Results
08:01pm, Monday, 04'th May 2020
SAN DIEGO, May 04, 2020 -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular.
Why Earnings Season Could Be Great for Fate Therapeutics (FATE)
01:38pm, Monday, 04'th May 2020
Fate Therapeutics (FATE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Why Earnings Season Could Be Great for Fate Therapeutics (FATE)
12:00am, Monday, 04'th May 2020Analysts' Weekly Ratings Changes for Fate Therapeutics (FATE)
08:52am, Friday, 01'st May 2020
Several brokerages have updated their recommendations and price targets on shares of Fate Therapeutics (NASDAQ: FATE) in the last few weeks: 4/28/2020 – Fate Therapeutics was upgraded by analysts at
Did The Underlying Business Drive Fate Therapeutics’ (NASDAQ:FATE) Lovely 576% Share Price Gain?
03:24pm, Thursday, 30'th Apr 2020
For us, stock picking is in large part the hunt for the truly magnificent stocks. Mistakes are inevitable, but a...
3 Monster Growth Stocks That Are Still Undervalued
12:33pm, Thursday, 30'th Apr 2020
The market is on the move, and this time stocks took off on an upward trajectory. On Wednesday April 29, all three of the major U.S. stock indexes posted gains at the closing bell, climbing higher on
